135 related articles for article (PubMed ID: 38596550)
21. Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy.
Vamos M; Healey JS; Wang J; Connolly SJ; Mabo P; Van Erven L; Kautzner J; Glikson M; Neuzner J; O'Hara G; Vinolas X; Gadler F; Hohnloser SH
Heart Rhythm; 2018 Mar; 15(3):386-392. PubMed ID: 29157723
[TBL] [Abstract][Full Text] [Related]
22. Etiology-specific assessment of predictors of long-term survival in chronic systolic heart failure.
Franke J; Zugck C; Hochadel M; Hack A; Frankenstein L; Zhao JD; Ehlermann P; Nelles M; Zeymer U; Winkler R; Zahn R; Katus HA; Senges J
Int J Cardiol Heart Vasc; 2015 Jun; 7():61-68. PubMed ID: 28785647
[TBL] [Abstract][Full Text] [Related]
23. Survival and arrhythmic risk among ischemic and non-ischemic heart failure patients with prophylactic implantable cardioverter defibrillator only therapy: A propensity score-matched analysis.
Briongos-Figuero S; Estévez A; Luisa Pérez M; Martínez-Ferrer JB; García E; Viñolas X; Arenal Á; Alzueta J; Basterra N; Rodríguez A; Lozano I; Muñoz-Aguilera R
Int J Cardiol; 2019 Jan; 274():163-169. PubMed ID: 30206014
[TBL] [Abstract][Full Text] [Related]
24. The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
Ruwald AC; Pietrasik G; Goldenberg I; Kutyifa V; Daubert JP; Ruwald MH; Jons C; McNitt S; Wang P; Zareba W; Moss AJ
J Am Coll Cardiol; 2014 Apr; 63(12):1190-1197. PubMed ID: 24333490
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy.
Gu M; Jin H; Hua W; Fan XH; Niu HX; Tian T; Ding LG; Wang J; Xue C; Zhang S
J Geriatr Cardiol; 2017 Apr; 14(4):238-244. PubMed ID: 28663761
[TBL] [Abstract][Full Text] [Related]
26. Long-term clinical outcomes after placement of an implantable cardioverter-defibrillator: does the etiology of heart failure matter?
Wasiak M; Tajstra M; Pyka Ł; Gąsior M
Kardiol Pol; 2020 Apr; 78(4):318-324. PubMed ID: 32200617
[TBL] [Abstract][Full Text] [Related]
27. Rapid-rate nonsustained ventricular tachycardias in high-risk dilated cardiomyopathy patients.
Lee WC; Watanabe M; Yokoshiki H; Temma T; Kamada R; Takahashi M; Hagiwara H; Takahashi Y; Anzai T
Pacing Clin Electrophysiol; 2020 Oct; 43(10):1086-1095. PubMed ID: 32735041
[TBL] [Abstract][Full Text] [Related]
28. A cohort study of cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy.
Martinelli Filho M; de Lima Peixoto G; de Siqueira SF; Martins SAM; Nishioka SAD; Pedrosa AAA; Teixeira RA; Dos Santos JX; Costa R; Kalil Filho R; Ramires JAF
Europace; 2018 Nov; 20(11):1813-1818. PubMed ID: 29509903
[TBL] [Abstract][Full Text] [Related]
29. Differences in mode of death between men and women receiving implantable cardioverter-defibrillators or cardiac resynchronization therapy in the MADIT trials.
Tompkins CM; Zareba W; Greenberg H; Goldstein R; McNitt S; Polonsky B; Brown M; Kutyifa V
Heart Rhythm; 2023 Jan; 20(1):39-45. PubMed ID: 36007729
[TBL] [Abstract][Full Text] [Related]
30. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
[TBL] [Abstract][Full Text] [Related]
31. Benefit of Catheter Ablation for Atrial Fibrillation in Heart Failure Patients with Different Etiologies.
Long S; Sun Y; Xiao X; Wang Z; Sun W; Gao L; Xia Y; Yin X
J Cardiovasc Dev Dis; 2023 Oct; 10(10):. PubMed ID: 37887884
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of precedent asymptomatic non-sustained ventricular tachycardias on subsequent ICD interventions and heart failure hospitalization in primary prevention ICD patients.
Makimoto H; Zielke S; Clasen L; Lin T; Gerguri S; Müller P; Schmidt J; Bejinariu A; Kurt M; Brinkmeyer C; Stern M; Kelm M; Fürnkranz A
Eur J Med Res; 2020 Mar; 25(1):5. PubMed ID: 32183891
[TBL] [Abstract][Full Text] [Related]
33. Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.
Borne RT; Masoudi FA; Curtis JP; Zipse MM; Sandhu A; Hsu JC; Peterson PN
JAMA Netw Open; 2021 Jan; 4(1):e2035470. PubMed ID: 33496796
[TBL] [Abstract][Full Text] [Related]
34. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL
J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882
[TBL] [Abstract][Full Text] [Related]
35. Sex Differences in Device Therapies for Ventricular Arrhythmias or Death in the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT-CRT) Trial.
Tompkins CM; Kutyifa V; Arshad A; McNitt S; Polonsky B; Wang PJ; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2015 Aug; 26(8):862-871. PubMed ID: 25929699
[TBL] [Abstract][Full Text] [Related]
36. Differences in predictors of implantable cardioverter-defibrillator therapies in patients with ischaemic and non-ischaemic cardiomyopathies.
Darma A; Nedios S; Kosiuk J; Richter S; Doering M; Arya A; Rolf S; Sommer P; Hindricks G; Bollmann A
Europace; 2016 Mar; 18(3):405-12. PubMed ID: 26056190
[TBL] [Abstract][Full Text] [Related]
37. Significance of abnormal and late ventricular signals in ventricular tachycardia ablation of ischemic and nonischemic cardiomyopathies.
Zachariah D; Nakajima K; Limite LR; Zweiker D; Spartalis M; Zirolia D; Musto M; D'Angelo G; Paglino G; Baratto F; Cireddu M; Bisceglia C; Radinovic A; Marzi A; Sala S; Peretto G; Vergara P; Gulletta S; Mazzone P; Della Bella P; Frontera A
Heart Rhythm; 2022 Dec; 19(12):2075-2083. PubMed ID: 35964871
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Mesenchymal Stem Cell Efficacy in Ischemic Versus Nonischemic Dilated Cardiomyopathy.
Tompkins BA; Rieger AC; Florea V; Banerjee MN; Natsumeda M; Nigh ED; Landin AM; Rodriguez GM; Hatzistergos KE; Schulman IH; Hare JM
J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 30005555
[TBL] [Abstract][Full Text] [Related]
39. Impact of the right ventricular lead position on clinical outcome and on the incidence of ventricular tachyarrhythmias in patients with CRT-D.
Kutyifa V; Bloch Thomsen PE; Huang DT; Rosero S; Tompkins C; Jons C; McNitt S; Polonsky B; Shah A; Merkely B; Solomon SD; Moss AJ; Zareba W; Klein HU
Heart Rhythm; 2013 Dec; 10(12):1770-7. PubMed ID: 23973954
[TBL] [Abstract][Full Text] [Related]
40. Characteristics of ventricular tachyarrhythmias and their susceptibility to antitachycardia pacing termination in patients with ischemic and nonischemic cardiomyopathy: A patient-level meta-analysis of three large clinical trials.
Cheng A; Joung B; Brown ML; Koehler J; Lexcen DR; Sanders P; Ellenbogen KA
J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2720-2726. PubMed ID: 32700390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
